Adjuvant therapy including 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by weekly paclitaxel was associated with a slight but significant improvement in disease-free survival versus FAC alone in patients with high-risk, node-negative breast cancer, according to results of the first efficacy analysis presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.
After participating in this educational activity, participants should be better able to:
Evaluate the role of a sequential weekly addition of paclitaxel to cytotoxic agent protocols in patients with high-risk node-negative breast cancer.
Identify the hematologic and nonhematologic toxicities associated with FAC and FAC-paclitaxel in high-risk node-negative breast cancer patients.